Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 18/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698878 | 0.93 | HDAC11 (0.48) | PTGESHDAC11 | |
| SCHEMBL5522106 | 0.90 | PTGES (0.49) | PTGESALOX5 | |
| SCHEMBL5523581 | 0.82 | LCK (0.43) | PTGESHDAC11ALOX5 | |
| SCHEMBL2699063 | 0.81 | PTGES (0.40) | PTGESALOX5 | |
| SCHEMBL16318318 | 0.81 | HDAC11 (0.52) | PTGESHDAC11 | |
| SCHEMBL2698885 | 0.78 | PTGES (0.38) | PTGESALOX5 | |
| SCHEMBL15324641 | 0.78 | PTGES (0.51) | PTGES | |
| SCHEMBL1964863 | 0.77 | HDAC11 (0.47) | PTGESHDAC11 | |
| SCHEMBL15324265 | 0.77 | PTGES (0.51) | PTGESALOX5 | |
| SCHEMBL2700066 | 0.76 | PTGES (0.57) | PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | PTGES 1/4885HDAC11 1336/4885ALOX5 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.